Early access
Sign in
Taking people in FrancePhase 4

Long-term safety of pirtobrutinib in people with blood cancers

Tests long-term safety of pirtobrutinib in adults with chronic lymphocytic leukemia or lymphoma.

Key facts

Who runs it
Eli Lilly and Company
Where
Nantes, FranceSee the siteAlso in 7 other countries, 34 sites
Trial code
Registry title
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Status
Recruiting
Phase
Phase 4
People taking part
279 people, planned
Started
20 May 2025
Expected to end
Dec 2032
Type of study
Interventional
Treatments tested
  • Pirtobrutinib
Record updated
2 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people who are already in study LOXO-BTK-18001 for chronic lymphocytic leukemia or non-Hodgkin lymphoma and want to keep taking pirtobrutinib or stay in follow-up.

Age
18 years or older
Sex
All sexes can join
Earlier treatment
Must be currently enrolled and active in study LOXO-BTK-18001: taking the study treatment, or in short-term or long-term follow-up.

Main reasons for not taking part

  • Took part in the Phase 1b cohort of study LOXO-BTK-18001

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:; receiving study intervention; in the short-term follow-up period, or; in the long-term follow-up period

Who cannot take part

  • Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001

Where in France

Also in 7 other countries, 34 sites

  • CHU de Nantes - Hôtel DieuNantes, FranceContact: Thomas Gastinne (principal investigator)Taking people

About the trial

What the trial wants to find out

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

The group in the trial

  • JZ01 PirtobrutinibTreatment being tested

    Participants receive pirtobrutinib as defined in the originator study (LOXO-BTK-18001/J2N-OX-JZNA). Pirtobrutinib administered orally.

    Treatment: Pirtobrutinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Plain-language title
Long-term safety of pirtobrutinib in people with blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 March 2026